27 results on '"Marcelo Borges Cavalcante"'
Search Results
2. Biomarkers of acute kidney injury in pediatric cardiac surgery
- Author
-
Isabel Cristina Leite Maia, Ronald Guedes Pompeu, Anna Karina Martins Brito, Alexandre Braga Libório, Candice Torres de Melo Bezerra Cavalcante, Titus Chan, Marcelo Borges Cavalcante, Klebia Magalhães Pereira Castello Branco, and Andrea Consuelo de Oliveira Telles
- Subjects
Heart Defects, Congenital ,Nephrology ,medicine.medical_specialty ,Heart disease ,030232 urology & nephrology ,Renal function ,Urine ,030204 cardiovascular system & hematology ,Lipocalin ,urologic and male genital diseases ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Cardiac Surgical Procedures ,Child ,biology ,urogenital system ,business.industry ,Acute kidney injury ,Acute Kidney Injury ,medicine.disease ,female genital diseases and pregnancy complications ,3. Good health ,Cardiac surgery ,Cystatin C ,Pediatrics, Perinatology and Child Health ,biology.protein ,business ,Biomarkers - Abstract
Acute kidney injury (AKI) is characterized by a sudden decrease in kidney function. Children with congenital heart disease are a special group at risk of developing AKI. We performed a systematic review of the literature to search for studies reporting the usefulness of novel urine, serum, and plasma biomarkers in the diagnosis and progression of AKI and their association with clinical outcomes in children undergoing pediatric cardiac surgery. In thirty studies, we analyzed the capacity to predict AKI and poor outcomes of five biomarkers: Cystatin C, Neutrophil gelatinase-associated lipocalin, Interleukin-18, Kidney injury molecule-1, and Liver fatty acid-binding protein. In conclusion, we suggest the need for further meta-analyses with the availability of additional studies.
- Published
- 2021
3. COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding
- Author
-
Luciana Azôr Dib, Paula Vitória Pereira Motoyama, Marcelo Borges Cavalcante, Edward Araujo Júnior, Marcelo Gondim Rocha, Dennyse Araújo Andrade, Ana Catherine Sampaio Braga, Mariana Albuquerque Montenegro, Candice Torres de Melo Bezerra Cavalcante, and Paula Andrade Neiva Santos
- Subjects
Pediatrics ,medicine.medical_specialty ,breastfeeding ,Middle East respiratory syndrome coronavirus ,viruses ,Breastfeeding ,Review ,Disease ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,Obstetrics and Gynaecology ,Maternity and Midwifery ,Pandemic ,Epidemiology ,Medicine ,GebFra Science ,030212 general & internal medicine ,Young adult ,030304 developmental biology ,0303 health sciences ,Pregnancy ,SARS-CoV-2 ,business.industry ,COVID-19 ,Obstetrics and Gynecology ,Stillen ,medicine.disease ,antiviral ,Symptomatic relief ,Schwangerschaft ,pregnancy ,business - Abstract
In December 2019, a new viral respiratory infection known as coronavirus disease 2019 (COVID-19) was first diagnosed in the city of Wuhan, China. COVID-19 quickly spread across the world, leading the World Health Organization to declare it a pandemic on March 11, 2020. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a similar virus to those involved in other epidemics such as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Epidemiological studies have shown that COVID-19 frequently affects young adults of reproductive age and that the elderly and patients with chronic disease have high mortality rates. Little is known about the impact of COVID-19 on pregnancy and breastfeeding. Most COVID-19 cases present with mild flu-like symptoms and only require treatment with symptomatic relief medications, whereas other cases with COVID-19 require treatment in an intensive care unit. There is currently no specific effective treatment for COVID-19. A large number of drugs are being used to fight infection by SARS-CoV-2. Experience with this therapeutic arsenal has been gained over the years in the treatment of other viral, autoimmune, parasitic, and bacterial diseases. Importantly, the search for an effective treatment for COVID-19 cannot expose pregnant women infected with SARS-CoV-2 to the potential teratogenic risks of these drugs. Therefore, it is necessary to determine and understand the safety of anti-COVID-19 therapies prior to conception and during pregnancy and breastfeeding.Im Dezember 2019 wurde erstmals eine neue virale Atemwegserkrankung, die den Namen Coronavirus-Erkrankung 2019 (COVID-19) bekam, in der chinesischen Stadt Wuhan diagnostiziert. COVID-19 verbreitete sich rasch über die ganze Welt, was die Weltgesundheitsorganisation veranlasste, am 11. März 2020 eine Pandemie auszurufen. Die neuartige Erkrankung wird von einem Virus aus der Familie der Coronaviridae hervorgerufen und wird SARS-CoV-2 (
- Published
- 2021
4. Dasatinib plus quercetin prevents uterine age-related dysfunction and fibrosis in mice
- Author
-
Allancer D. C. Nunes, Michal M. Masternak, Augusto Schneider, James L. Kirkland, Tatiana D. Saccon, Tamara Tchkonia, and Marcelo Borges Cavalcante
- Subjects
Aging ,medicine.medical_specialty ,mRNA ,Dasatinib ,Uterus ,AKT1 ,Antioxidants ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Downregulation and upregulation ,Fibrosis ,Internal medicine ,Gene expression ,medicine ,Animals ,Senolytic ,Protein Kinase Inhibitors ,PI3K/AKT/mTOR pathway ,miRNA ,030304 developmental biology ,Uterine Diseases ,0303 health sciences ,business.industry ,Cell Biology ,medicine.disease ,3. Good health ,medicine.anatomical_structure ,Endocrinology ,030220 oncology & carcinogenesis ,senolytics ,Drug Therapy, Combination ,Female ,Quercetin ,business ,uterine fibrosis ,Research Paper ,medicine.drug - Abstract
The uterine fibrosis contributes to gestational outcomes. Collagen deposition in the uterus is related to uterine aging. Senolytic therapies are an option for reducing health complications related to aging. We investigated effects of aging and the senolytic drug combination of dasatinib plus quercetin (D+Q) on uterine fibrosis. Forty mice, 20 young females (03-months) and 20 old females (18-months), were analyzed. Young (Y) and old (O) animals were divided into groups of 10 mice, with one treatment (T) group (YT and OT) and another control © group (YC and OC). Comparative analysis of Pi3k/Akt1/mTor and p53 gene expression and related microRNAs (miR34a, miR34b, miR34c, miR146a, miR449a, miR21a, miR126a, and miR181b) among groups was performed to test effects of age and treatment on collagen deposition pathways. Aging promoted downregulation of the Pi3k/Akt1/mTor signaling pathway (P = 0.005, P = 0.031, and P = 0.028, respectively) as well as a reduction in expression of miR34c (P = 0.029), miR126a (P = 0.009), and miR181b (P = 0.007). D+Q treatment increased p53 gene expression (P = 0.041) and decreased miR34a (P = 0.016). Our results demonstrate a role for the Pi3k/Akt1/mTor signaling pathway in uterine aging and suggest for the first time a possible anti-fibrotic effect in the uterus of D+Q senolytic therapy.
- Published
- 2020
5. Coagulation Biomarkers in Women with Recurrent Miscarriage and Polycystic Ovarian Syndrome: Systematic Review and Meta-Analysis
- Author
-
Marcelo Borges Cavalcante, Manoel Sarno, Ricardo Barini, Candice Torres de Melo Bezerra Cavalcante, and Edward Araujo Júnior
- Subjects
medicine.medical_specialty ,Thrombophilia ,Miscarriage ,polymorphism ,Internal medicine ,gestörte Ovarfunktion ,Maternity and Midwifery ,Recurrent miscarriage ,medicine ,Factor V Leiden ,GebFra Science ,biology ,business.industry ,Obstetrics and Gynecology ,Odds ratio ,medicine.disease ,Polycystic ovary ,abortion ,Polymorphismus ,Fehlgeburt ,Methylenetetrahydrofolate reductase ,Meta-analysis ,biology.protein ,biomarker ,Original Article ,business ,disturbed ovarian function - Abstract
Introduction Pregnant women with polycystic ovarian syndrome (PCOS) have high risk of pregnancy loss. Pathophysiological mechanisms appear to be associated with obesity, hormonal factors, or blood clotting disorders. Our aim is to perform a systematic review and meta-analysis on the relationship between coagulation disorders and risk of recurrent miscarriage (RM) in patients with PCOS and to identify coagulation biomarkers for this condition. Material and Methods PubMed and MEDLINE databases were searched for publications in English language. The search terms used included “RM”, “polycystic ovary syndrome”, “coagulation disorders”, and “thrombophilia”. Odds ratios (ORs) and 95% confidence intervals (CIs) for miscarriage in different RM groups (with and without PCOS). Results A total of 575 publications including the search terms were identified. Six studies were included for qualitative analysis, and five were included for quantitative analysis (meta-analysis). We found no association between RM and inherited thrombophilias in patients with PCOS: (1) Factor V Leiden (OR, 0.74; 95% CI, 0.38 – 1.45; p = 0.38); (2) C677T methylenetetrahydrofolate reductase polymorphism (MTHFR) (OR, 1.01; 95% CI, 0.64 – 1.59; p = 0.97); and (3) A1297C MTHFR polymorphism (OR, 1.08; 95% CI, 0.62 – 1.89; p = 0.77). Other potential biomarkers were identified, with emphasis on plasminogen activator inhibitor type 1. Conclusion Data available in the current literature revealed that there was no association between RM and inherited thrombophilias in patients with PCOS. RM patients with PCOS have a high risk of thromboembolic events.
- Published
- 2019
6. Reply to letter to the editor. [Carta]: 'Safety of lymphocytes immunotherapy during the COVID-19 outbreak in Wuhan, China'
- Author
-
Fabricio da Silva Costa, Marcelo Borges Cavalcante, Manoel Sarno, Edward Araujo Júnior, and Ricardo Barini
- Subjects
medicine.medical_specialty ,2019-20 coronavirus outbreak ,Letter to the editor ,Coronavirus disease 2019 (COVID-19) ,business.industry ,General surgery ,medicine.medical_treatment ,Reproductive medicine ,Obstetrics and Gynecology ,Outbreak ,Immunotherapy ,General Medicine ,medicine.disease ,SURTOS DE DOENÇAS ,Recurrent miscarriage ,Obstetrics and Gynaecology ,medicine ,China ,business - Abstract
Dear Editor, It was with great interest that we read and analyzed the letter to the editor of Xiang et al. The authors presented initial outcomes on the safety of lymphocyte immunotherapy (LIT) in a group of patients diagnosed with alloimmune recurrent miscarriage (RM) during November 1, 2019–January 17, 2020 in Center of Reproductive Medicine, Tongji Medical College, Huazhong University of Science and Technology.
- Published
- 2021
7. Intrauterine perfusion immunotherapies in recurrent implantation failures: Systematic review
- Author
-
Manoel Sarno, Marcelo Borges Cavalcante, Candice Torres de Melo Bezerra Cavalcante, and Ricardo Barini
- Subjects
0301 basic medicine ,medicine.medical_specialty ,medicine.medical_treatment ,Immunology ,MEDLINE ,Blood Transfusion, Intrauterine ,Chorionic Gonadotropin ,Human chorionic gonadotropin ,03 medical and health sciences ,0302 clinical medicine ,Implantation failure ,Pregnancy ,Internal medicine ,Granulocyte Colony-Stimulating Factor ,medicine ,Humans ,Immunology and Allergy ,Embryo Implantation ,030219 obstetrics & reproductive medicine ,Assisted reproductive technology ,Platelet-Rich Plasma ,business.industry ,Pregnancy Outcome ,Obstetrics and Gynecology ,Granulocyte colony-stimulating factor ,Pregnancy Complications ,030104 developmental biology ,Systematic review ,Reproductive Medicine ,Leukocytes, Mononuclear ,Gestation ,Female ,Immunotherapy ,business ,Perfusion - Abstract
Studies have investigated the gestational outcomes of new immunological therapies in the treatment of patients with recurrent implantation failure (RIF) in assisted reproductive technology (ART). The objective of this article is to assess the current state of evidence available in the literature on intrauterine perfusion immunotherapies in women undergoing ART treatments. By considering the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA), the authors performed systematic review by searching the databases of PubMed/MEDLINE and Scopus using the following key words: "recurrent implantation failure," "intrauterine infusion," "Platelet-Rich Plasma (PRP)," "Peripheral Blood Mononuclear Cells (PBMC)," "Granulocyte Colony-Stimulating Factor (G-CSF)," and "Human Chorionic Gonadotropin (hCG)." The authors analyzed the indications and the impact of new immunological therapies with intrauterine infusions on the pregnancy outcomes of patients undergoing ART. PRP, PBMC, G-CSF, and hCG were the four most used immunological therapies with intrauterine infusion. These new therapies appear to improve the results of ART treatments in cases of RIF. However, the small number of studies does not allow definitive conclusions about the effectiveness of these therapies.
- Published
- 2020
8. Obesity and recurrent miscarriage: A systematic review and meta-analysis
- Author
-
Edward Araujo Júnior, Ricardo Barini, Marcelo Borges Cavalcante, Manoel Sarno, and Alberto Borges Peixoto
- Subjects
Pregnancy ,medicine.medical_specialty ,030219 obstetrics & reproductive medicine ,business.industry ,Obstetrics ,Obstetrics and Gynecology ,Odds ratio ,Overweight ,medicine.disease ,Obesity ,Miscarriage ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Meta-analysis ,Recurrent miscarriage ,Medicine ,medicine.symptom ,business ,Body mass index - Abstract
The aim of this study is to perform a systematic review and meta-analysis on the relationship between excess weight and risk of recurrent pregnancy loss (RPL) and to highlight the common immunological mechanisms of these two conditions. The PubMed and MEDLINE databases were searched for publications in English available as of November 2017. The search terms used were 'recurrent pregnancy loss', 'body mass index' (BMI), 'overweight' and 'obesity'. For calculation of the odds ratio (OR) and 95% confidence intervals (CI) for miscarriage in different BMI groups, RevMan software was used (Review Manager, Version 5.3.5 for Windows; The Cochrane Collaboration). In total, 100 publications including the search terms were identified. Six studies were included for qualitative analysis, and two studies were included for quantitative analysis (meta-analysis). The association between excess weight and RPL was significant (OR, 1.34; 95% CI, 1.05-1.70; P = 0.02). The isolated analyses of the groups of obese and overweight women revealed an association only between obesity and RPL (OR, 1.75; 95% CI, 1.24-2.47; P = 0.001). The data available in the current literature revealed that obese women with a history of RPL have a high risk of future pregnancy losses, a risk which was not found among overweight women.
- Published
- 2018
9. COVID-19 and miscarriage: From immunopathological mechanisms to actual clinical evidence
- Author
-
Marcelo Borges Cavalcante, Ana Nery Melo Cavalcante, Manoel Sarno, Candice Torres de Melo Bezerra Cavalcante, Joanne Kwak-Kim, and Ricardo Barini
- Subjects
medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Middle East respiratory syndrome coronavirus ,viruses ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immunology ,Review Article ,Miscarriage ,medicine.disease_cause ,Pregnancy loss ,Pregnancy ,Prevalence ,Humans ,Immunology and Allergy ,Medicine ,Pregnancy Complications, Infectious ,SARS-CoV-2 ,business.industry ,Obstetrics ,COVID-19 ,virus diseases ,Obstetrics and Gynecology ,medicine.disease ,Obstetrical outcomes ,Abortion, Spontaneous ,Reproductive Medicine ,Clinical evidence ,Gestation ,Female ,Observational study ,business - Abstract
The association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the first half of pregnancy and pregnancy loss is still unknown. Infections by other coronaviruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV), appear to increase the risk of miscarriage. The purpose of this study is to assess whether SARS-CoV-2 infection increases the risk of miscarriage. Firstly, a narrative review of the literature on animal and human studies was performed to analyze the immunopathological mechanisms of SARS-CoV-2 infection during preconception and early pregnancy, by which it may increase the risk of miscarriage. Secondly, a systematic review/meta-analysis of studies was conducted to assess the prevalence of miscarriage in COVID-19 patients diagnosed during pregnancy. Meta-analysis of proportions was used to combine data, and pooled proportions were reported. Seventeen case series and observational studies and 10 prevalence meta-analyses were selected for the review. The estimate of the overall miscarriage rate in pregnant women with COVID-19 was 15.3 % (95 % CI 10.94–20.59) and 23.1 (95 % CI 13.17–34.95) using fixed and random effect models, respectively. Based on the data in the current literature, the miscarriage rate (
- Published
- 2021
10. Is there any possible link between COVID-19 and human infertility?
- Author
-
Arlley Cleverson Belo da Silva, Ricardo Barini, Edward Araujo Júnior, Marcelo Borges Cavalcante, and Manoel Sarno
- Subjects
0301 basic medicine ,Infertility ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,MEDLINE ,medicine.disease_cause ,World health ,03 medical and health sciences ,0302 clinical medicine ,Obstetrics and Gynaecology ,medicine ,Humans ,Pediatrics, Perinatology, and Child Health ,Coronavirus ,business.industry ,COVID-19 ,Obstetrics and Gynecology ,Outbreak ,medicine.disease ,030104 developmental biology ,030220 oncology & carcinogenesis ,Family medicine ,Pediatrics, Perinatology and Child Health ,business - Abstract
Currently, we are facing a new outbreak of coronavirus infection that started in December 2019 in China and is already present in more than sixty other countries. The World Health Organization (WHO...
- Published
- 2020
11. Lymphocyte immunotherapy in the treatment of recurrent miscarriage: systematic review and meta-analysis
- Author
-
Marcelo Borges Cavalcante, Ricardo Barini, Fabricio da Silva Costa, Edward Araujo Júnior, and Manoel Sarno
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Pregnancy ,030219 obstetrics & reproductive medicine ,business.industry ,medicine.medical_treatment ,MEDLINE ,Obstetrics and Gynecology ,General Medicine ,Immunotherapy ,Cochrane Library ,Abortion ,medicine.disease ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Internal medicine ,Meta-analysis ,Recurrent miscarriage ,Immunology ,medicine ,Live birth ,business - Abstract
Recurrent miscarriage (RM) affects up to 2–3% of couples of reproductive age. There are several causes for this condition, including immunologic. The embryo is considered an allograft, subject to the rejection mechanisms of the maternal immune system. Immunotherapy involving immunization with lymphocytes is considered in cases of idiopathic RM. However, there is still no consensus regarding the efficacy and safety of this therapy. This systematic review and meta-analysis evaluated the data available in the literature regarding the efficacy and safety of the use of immunotherapy with lymphocytes in couples with history of RM. Searches in PubMed/Medline, SCOPUS, and Cochrane Library databases were conducted, using the following keywords: “recurrent miscarriage,” “lymphocyte immunotherapy,” and “meta-analysis.” Statistical analyses were performed using Review Manager 5.3 (RevMan), version 5.3. Six published meta-analysis were retrieved; two found no improvements in the rate of live births after the use of immunization with lymphocytes in the treatment of RM, and four found a beneficial effect of the use of immunotherapy with lymphocytes in cases of RM, with significant improvements in the rate of live births. Data available in the literature supports the efficacy and safety of immunotherapy with lymphocytes in cases of RM without an identified cause.
- Published
- 2016
12. Dasatinib Plus Quercetin on Uterine Age-Related Dysfunction and Fibrosis in Mice
- Author
-
James L. Kirkland, Tatiana D. Saccon, Allancer D. C. Nunes, Tamara Tchkonia, Michal M. Masternak, Marcelo Borges Cavalcante, and Augusto Schneider
- Subjects
0303 health sciences ,medicine.medical_specialty ,business.industry ,Uterus ,AKT1 ,medicine.disease ,3. Good health ,Dasatinib ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,medicine.anatomical_structure ,Downregulation and upregulation ,Fibrosis ,030220 oncology & carcinogenesis ,Internal medicine ,Gene expression ,medicine ,Gestation ,business ,PI3K/AKT/mTOR pathway ,030304 developmental biology ,medicine.drug - Abstract
Female reproductive function is negatively impacted by age. Animal and human studies show that fibrosis of the uterus contributes to gestational outcomes. Collagen deposition in the myometrial and endometrial layers is the main change related to uterine aging. Senolytic therapies are a potential option for reducing diseases and health complications related to aging. We investigated effects of aging and the senolytic drug combination of dasatinib plus quercetin (D+Q) on uterine fibrosis. A total of 40 mice, 20 young females (03-months) and 20 old females (18-months), were analyzed. Young (Y) and old (O) animals were divided into groups of 10 mice, with one treatment (T) group (YT and OT) and another control (C) group (YC and OC). Comparative analysis ofPi3k/Akt1/mTorand p53 gene expression among the 4 groups was performed to test effects of age and treatment on collagen deposition in uterine tissue. Uterine levels of microRNAs (miR34a, miR34b, miR34c, miR146a, miR449a, miR21a, miR126a, and miR181b) were evaluated. Aging promoted downregulation of genes of thePi3k/Akt1/mTorsignaling pathway (p=0.005, p=0.031, and p=0.028, respectively) as well as a reduction in expression of miR34c (p=0.029), miR126a (p=0.009), and miR181b (p=0.007). D+Q treatment increased p53 gene expression (p=0.041) and decreased levels of miR34a (p=0.016). Our results demonstrate a role for thePi3k/Akt1/mTorsignaling pathway in uterine aging and suggest for the first time a possible anti-fibrotic effect in the uterus of D+Q senolytic therapy.
- Published
- 2019
13. The enigmatic role of growth hormone in age-related diseases, cognition, and longevity
- Author
-
Andrzej Bartke, Tamara Tchkonia, Marcelo Borges Cavalcante, Augusto Schneider, Darlene E. Berryman, Derek M. Huffman, Michal M. Masternak, Ed List, John J. Kopchick, Tatiana D. Saccon, Gabriela Colon, Nicolas Musi, James L. Kirkland, and Yuji Ikeno
- Subjects
medicine.medical_specialty ,Aging ,business.industry ,Human Growth Hormone ,media_common.quotation_subject ,Longevity ,Cancer ,Cognition ,Review ,Growth hormone ,medicine.disease ,Molecular medicine ,Endocrinology ,medicine.anatomical_structure ,Anterior pituitary ,Internal medicine ,Diabetes mellitus ,Medicine ,Humans ,Geriatrics and Gerontology ,business ,GH Deficiency ,media_common - Abstract
Growth hormone (GH) is secreted by the anterior pituitary gland and regulates various metabolic processes throughout the body. GH and IGF-1 levels are markedly reduced in older humans, leading some to hypothesize GH supplementation could be a viable “anti-aging” therapy. However, there is still much debate over the benefits and risks of GH administration. While an early study of GH administration reported reduced adiposity and lipid levels and increased bone mineral density, subsequent studies failed to show significant benefits. Conversely, other studies found positive effects of GH deficiency including extended life span, improved cognitive function, resistance to diseases such as cancer and diabetes, and improved insulin sensitivity despite a higher fat percentage. Thus, the roles of GH in aging and cognition remain unclear, and there is currently not enough evidence to support use of GH as an anti-aging or cognitive impairment therapy. Additional robust and longer-duration studies of efficacy and safety of GH administration are needed to determine if modulating GH levels could be a successful strategy for treating aging and age-related diseases.
- Published
- 2019
14. Perinatal unusual rhabdomyoma location - case report and systematic reviews of the literature
- Author
-
Marcelo Borges Cavalcante, Edward Araujo Júnior, Fabio Rocha Fernandes Tavora, Jeanne Araújo Bandeira, Valdester Cavalcante Pinto Júnior, Klébia Magalhães P. Castello Branco, Andrea Consuelo de Oliveira Teles, Ana Cristina Perez Zamarian, Ronald Guedes Pompeu, Isabel Cristina Leite Maia, and Candice Torres de Melo Bezerra Cavalcante
- Subjects
Pediatrics ,medicine.medical_specialty ,Perinatal outcome ,Prenatal diagnosis ,030204 cardiovascular system & hematology ,Rhabdomyoma ,Heart Neoplasms ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Tuberous Sclerosis ,030225 pediatrics ,Prenatal Diagnosis ,medicine ,Humans ,Surgical treatment ,business.industry ,Cardiac rhabdomyoma ,Infant, Newborn ,Obstetrics and Gynecology ,Arrhythmias, Cardiac ,medicine.disease ,Systematic review ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Female ,business - Abstract
Objective: To report a case of prenatal diagnosis of cardiac rhabdomyoma (CR) and neonatal surgical treatment as well as undertaking a systematic review of the literature to determine most frequent...
- Published
- 2019
15. Gestational and perinatal outcomes in recurrent miscarriages couples treated with lymphocyte immunotherapy
- Author
-
Marla Niag, Marcelo Borges Cavalcante, Ricardo Barini, Simone Lima, Tatiana Michelon, Edward Araujo Júnior, Ivana Luz, Bianca Figueiredo, Manoel Sarno, Isabela Nelly Machado, Kleber Pimentel, and Jorge Neumann
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Lymphocyte ,medicine.medical_treatment ,Perinatal outcome ,Lymphocyte immunotherapy ,lcsh:Gynecology and obstetrics ,Recurrent miscarriage ,03 medical and health sciences ,0302 clinical medicine ,medicine ,lcsh:RG1-991 ,Pregnancy ,030219 obstetrics & reproductive medicine ,business.industry ,Obstetrics ,Obstetrics and Gynecology ,Immunotherapy ,Perinatal outcomes ,medicine.disease ,Laboratory test ,030104 developmental biology ,medicine.anatomical_structure ,Reproductive Medicine ,Reproductive Medicine and Endocrinology ,Gestation ,Observational study ,business - Abstract
Objective: This study aims to elucidate which types of recurrent miscarriage (RM) patients experienced a livebirth after paternal lymphocyte immunotherapy (LIT) and to evaluate the perinatal outcome. Study design: Retrospective analysis of a multicenter, observational study which enrolled 1096 couples with a history of two or more spontaneous miscarriages without any intercalated delivery. We conducted an intention-to-treat analysis of couples with RM treated with or without LIT regarding to gestational and perinatal outcomes. We compared groups by using the Student’s t-test or Kruskal–Wallis test, Fisher’s exact-test and χ2 test when appropriate. Results: The success of gestation was significantly higher in the LIT group (60.1% vs. 33.1%; p
- Published
- 2018
16. Maternal immune responses and obstetrical outcomes of pregnant women with COVID-19 and possible health risks of offspring
- Author
-
Manoel Sarno, Joanne Kwak-Kim, Ricardo Barini, Marcelo Borges Cavalcante, and Candice Torres de Melo Bezerra Cavalcante
- Subjects
Risk ,medicine.medical_specialty ,Offspring ,Immunology ,Population ,Intrauterine growth restriction ,Review Article ,03 medical and health sciences ,0302 clinical medicine ,Child of Impaired Parents ,Pregnancy ,Obstetrics and Gynaecology ,Pandemic ,medicine ,Humans ,Immunology and Allergy ,Pregnancy Complications, Infectious ,Young adult ,education ,reproductive and urinary physiology ,Problem Behavior ,education.field_of_study ,Fetal Growth Retardation ,030219 obstetrics & reproductive medicine ,SARS-CoV-2 ,Obstetrics ,business.industry ,Transmission (medicine) ,Pregnancy Outcome ,COVID-19 ,Obstetrics and Gynecology ,medicine.disease ,Obstetrical outcomes ,Infectious Disease Transmission, Vertical ,Behavioral disorders ,Low birth weight ,Reproductive Medicine ,Maternal Exposure ,Premature Birth ,Female ,medicine.symptom ,business ,Immunity, Maternally-Acquired ,030215 immunology - Abstract
Highlights • Pregnant women with COVID-19 have proinflammatory immune responses. • Maternal COVID-19 is associated with increased risk of preterm birth, IUGR and LBW. • Vascular malperfusion, inflammation and thrombosis are major placental pathologies. • Placental pathologies may progress even in asymptomatic COVID-19 cases. • COVID-19 may increase long-term offspring risk for non-communicable disease., Coronavirus disease 2019 (COVID-19) pandemic has spread rapidly across the world. The vast majority of patients with COVID-19 manifest mild to moderate symptoms but may progress to severe cases or even mortalities. Young adults of reproductive age are the most affected population by SARS-CoV-2 infection. However, there is no consensus yet if pregnancy contributes to the severity of COVID-19. Initial studies of pregnant women have found that COVID-19 significantly increases the risk of preterm birth, intrauterine growth restriction, and low birth weight, which have been associated with non-communicable diseases in offspring. Besides, maternal viral infections with or without vertical transmission have been allied with neurological and behavioral disorders of the offspring. In this review, obstetrical outcomes of women with COVID-19 and possible risks for their offspring are discussed by reviewing maternal immune responses to COVID-19 based on the current evidence. Structural and systemic follow-up of offspring who are exposed to SARS-CoV-2 in-utero is suggested.
- Published
- 2021
17. COVID-19 and immunomodulation treatment for women with reproductive failures
- Author
-
Carolyn Coulam, Marcelo Borges Cavalcante, Qiaohua He, Sung Ki Lee, Lujain Alsubki, Atsushi Fukui, Toshifumi Takahashi, Wen Juan Wang, Jae Won Han, Ai-Hua Liao, Changsheng Huang, Ricardo Barini, Youssef Derbala, Nathalie Lédée, Wael Saab, Nayoung Sung, Shihua Bao, Xiuhua Yang, Ae-Ra Han, Joanne Kwak-Kim, and Kuniaki Ota
- Subjects
0301 basic medicine ,medicine.medical_specialty ,medicine.medical_treatment ,Pneumonia, Viral ,Immunology ,medicine.disease_cause ,Article ,Betacoronavirus ,03 medical and health sciences ,Human reproduction ,0302 clinical medicine ,Pregnancy ,Obstetrics and Gynaecology ,Health care ,Pandemic ,medicine ,Humans ,Immunology and Allergy ,Intensive care medicine ,Pandemics ,Coronavirus ,Reproductive health ,030219 obstetrics & reproductive medicine ,SARS-CoV-2 ,business.industry ,Reproductive failure ,COVID-19 ,Obstetrics and Gynecology ,Outbreak ,Immunotherapy ,medicine.disease ,Pregnancy Complications ,Reproductive Health ,030104 developmental biology ,Reproductive Medicine ,Female ,Coronavirus Infections ,business - Abstract
Highlights • Pregnant women with a history of reproductive failures with immune etiologies (RFI) are vulnerable to COVID-19 infection. • In pregnant women with RFI, including mild COVID-19 patients, low dose prednisone, heparin, tacrlolimus, plaquenil, and IVIg can be continued. • There is no clear evidence that anti-TNF drugs and intralipid infusion cannot be used in pregnant women with RFI during COVID-19 pandemic. • Those with severe COVID-19 infection, immunotherapy for RFI should be curtailed unless indicated for the management of COVID-19. • The current recommendation is based on observational studies with limited data, and validation studies are needed., COVID-19 pandemic is affecting various areas of health care, including human reproduction. Many women with reproductive failures, during the peri-implantation period and pregnancy, are on the immunotherapy using immune modulators and immunosuppressant due to underlying autoimmune diseases, cellular immune dysfunction, and rheumatic conditions. Many questions have been raised for women with immunotherapy during the COVID-19 pandemic, including infection susceptibility, how to manage women with an increased risk of and active COVID-19 infection. SARS-CoV-2 is a novel virus, and not enough information exists. Yet, we aim to review the data from previous coronavirus outbreaks and current COVID-19 and provide interim guidelines for immunotherapy in women with reproductive failures.
- Published
- 2020
18. Cytogenetic abnormalities in couples with a history of primary and secondary recurrent miscarriage: a Brazilian Multicentric Study
- Author
-
Bianca Figueiredo, Isabela Nelly Machado, Marcelo Borges Cavalcante, Marla Niag, Tatiana Michelon, Ivana Luz, Joanna Goes Castro Meira, Manoel Sarno, Ricardo Barini, Simone Lima, Kleber Pimentel, Jorge Neumann, Gabriela Gayer, and Edward Araujo Júnior
- Subjects
0301 basic medicine ,Adult ,Chromosome Aberrations ,Male ,medicine.medical_specialty ,Abortion, Habitual ,030219 obstetrics & reproductive medicine ,Obstetrics ,business.industry ,Obstetrics and Gynecology ,medicine.disease ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Sex Factors ,Pediatrics, Perinatology and Child Health ,Recurrent miscarriage ,medicine ,Humans ,Female ,business ,Retrospective Studies - Abstract
Objective: To evaluate the difference between chromosomal abnormalities between the gender of couples affected by Recurrent miscarriage (RM) and if there is an association between previous obstetri...
- Published
- 2018
19. Early treatment of intrapericardial teratoma: a case presentation and systematic literature review
- Author
-
Alberto Borges Peixoto, Klébia Magalhães P. Castello Branco, Edward Araujo Júnior, Candice Torres de Melo Bezerra Cavalcante, Ronald Guedes Pompeu, Marcelo Borges Cavalcante, Valdester Cavalcante Pinto Júnior, and João Victor Cabral Correia Férrer
- Subjects
Adult ,Male ,medicine.medical_specialty ,endocrine system diseases ,Perinatal outcome ,Gestational Age ,Case presentation ,030204 cardiovascular system & hematology ,Infant, Newborn, Diseases ,Ultrasonography, Prenatal ,Heart Neoplasms ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,030225 pediatrics ,parasitic diseases ,Medicine ,Humans ,business.industry ,Cesarean Section ,General surgery ,Infant, Newborn ,Teratoma ,Obstetrics and Gynecology ,medicine.disease ,Systematic review ,Intrapericardial teratoma ,Treatment Outcome ,Echocardiography ,Pediatrics, Perinatology and Child Health ,Female ,business - Abstract
To present a case of an early treatment of cardiac intraperitoneal teratoma (IPT) in a newborn and its associated systematic literature review.We presented a case of a newborn with IPT but without hydrops and having a good perinatal outcome after cardiac surgery. Using the PubMed database, we conducted a systematic literature review of articles regarding cases with cardiac IPT diagnosed and treated in the neonatal period and published in English from 2004 onward. We excluded cases that involved fetal death or interrupted gestation events.In total, 38 cases of IPT from 31 articles were included. The mean ± standard deviation of the gestational age at diagnosis and delivery were 27.9 ± 5.7 and 33.0 ± 3.5 weeks, respectively, and that of birth weight was 2373 ± 834.5 g. The majority of fetuses (42.1%) were males. Pericardial effusion was the most common symptom (60.5%) followed by hydrops (42.1%) and respiratory distress (42.1%). Intrauterine procedure was not performed in 63.1% of cases, and 71.0% of newborns were alive.IPT in newborns is usually associated with a good prognosis without the need for intrauterine procedures. Cases with IPT-related death are associated with hemodynamic impairment in fetuses with hydrops.
- Published
- 2018
20. Lymphocyte immunotherapy for recurrent miscarriages: Predictors of therapeutic success
- Author
-
Marla Niag, Ivana Luz, Edward Araujo Júnior, Bianca Figueiredo, Ricardo Barini, Simone Lima, Kleber Pimentel, Jorge Neumann, Isabela Nelly Machado, Manoel Sarno, Marcelo Borges Cavalcante, and Tatiana Michelon
- Subjects
0301 basic medicine ,Adult ,medicine.medical_specialty ,Abortion, Habitual ,Multivariate analysis ,Lymphocyte ,medicine.medical_treatment ,Immunology ,Thrombophilia ,Treatment failure ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Immunology and Allergy ,Humans ,Lymphocytes ,Autoantibodies ,Retrospective Studies ,Pregnancy ,030219 obstetrics & reproductive medicine ,Obstetrics ,business.industry ,Obstetrics and Gynecology ,Immunotherapy ,medicine.disease ,030104 developmental biology ,medicine.anatomical_structure ,Treatment success ,Reproductive Medicine ,Observational study ,Female ,business ,Brazil - Abstract
Problem To evaluate the predictors of successful pregnancies in women with a history of recurrent miscarriages (RMs) having undergone lymphocyte immunotherapy (LIT). Method of study Retrospective, multicenter, observational study which involved 702 pregnant women with history of RM treated with LIT. Comparative analysis of women with a history of RM having undergone LIT and experienced treatment success vs those having experienced treatment failure along with the analysis of the association between the number of prior miscarriages and the efficacy of LIT. Results A total of 421 women were able to carry the pregnancy to term, with treatment success rate of 60%. The multivariate analysis showed that age, the association between autoantibodies and thrombophilia, and the number of previous miscarriages were factors associated with LIT failure. Secondary RMs alone were not found to be a factor predictive of LIT success or failure; however, secondary RMs among women with a history of 5 or more RM were found to be a predictor of LIT success (OR: 10.24; 95% CI: 1.9-55.8; P = .007). Conclusion Age, the number of previous miscarriages, and the association between autoantibodies and thrombophilia are associated with LIT failure. A higher number of previous miscarriages in cases of secondary RM resulted in better LIT outcomes.
- Published
- 2017
21. Gastric contractility in experimental gastroschisis
- Author
-
Francisco J. Oliveira-Filho, Marcelo Borges Cavalcante, Marcellus H.L.P. Souza, Francisco J.B. Lima, Pedro Jorge Caldas Magalhães, Willy Okoba, Lourenço Sbragia, and Antônio Aldo Melo-Filho
- Subjects
medicine.medical_specialty ,Contraction (grammar) ,Carbachol ,In Vitro Techniques ,Contractility ,Internal medicine ,RATOS WISTAR (EXPERIMENTOS) ,medicine ,Animals ,Rats, Wistar ,Antrum ,Gastroschisis ,business.industry ,Stomach ,General Medicine ,medicine.disease ,Rats ,Disease Models, Animal ,medicine.anatomical_structure ,Endocrinology ,Fundus (uterus) ,Pediatrics, Perinatology and Child Health ,Surgery ,medicine.symptom ,business ,Muscle Contraction ,medicine.drug ,Muscle contraction - Abstract
Background/purpose The mechanism of fetal gastric dilation in gastroschisis is controversial. This study was designed to characterize changes in the contractile profile of strips of stomach from rats following experimental gastroschisis. Methods Pregnant Wistar rats were operated on day 18.5. Fetuses were divided into three groups: gastroschisis (G), sham (S), and control (C). On day 21.5, gastric fundus and antrum strips were obtained and suspended to a force transducer connected to a digital data acquisition system. They were submitted to increasing concentrations of carbachol (CCh) and weighed at the end of each procedure. Frequency and amplitude of each contraction were evaluated. Results Under basal conditions, spontaneous oscillatory contractions of antrum and fundus strips of G, S, and C were similar (P>0.05; ANOVA). However, cumulative concentrations of CCh (0.01–100μM) produced different effects in all groups and were characterized by a significant increase in amplitude and frequency of spontaneous contractions in antral smooth muscle and a sustained increase in tonus in fundic strips. Upon analysis, no significant difference in frequency or amplitude was noted in antral tissues comparing C to G and to S (P>0.05). No significant contractility difference was noted in fundic smooth muscle (comparing all groups, P >0.05), with the CCh-induced curve following a typical sigmoidal format, dependent on increasing concentrations (P Conclusions Gastric contractile responses to CCh are preserved in experimental gastroschisis. These results do not support the theory that gastric dilation occurs secondary to intestinal inflammation alone.
- Published
- 2013
22. Risk factors associated with a new pregnancy loss and perinatal outcomes in cases of recurrent miscarriage treated with lymphocyte immunotherapy
- Author
-
Edward Araujo Júnior, Ricardo Barini, Fabricio da Silva Costa, and Marcelo Borges Cavalcante
- Subjects
Adult ,medicine.medical_specialty ,Abortion, Habitual ,Adolescent ,Lymphocyte ,medicine.medical_treatment ,Miscarriage ,symbols.namesake ,Young Adult ,Pregnancy ,Risk Factors ,Recurrent miscarriage ,medicine ,Humans ,Lymphocytes ,Fisher's exact test ,Retrospective Studies ,Obstetrics ,business.industry ,Pregnancy Outcome ,Obstetrics and Gynecology ,Retrospective cohort study ,Immunotherapy ,Middle Aged ,medicine.disease ,medicine.anatomical_structure ,Pediatrics, Perinatology and Child Health ,Etiology ,symbols ,Female ,business - Abstract
To assess the perinatal outcomes and risk factors for further pregnancy loss in patients with recurrent miscarriage treated with lymphocyte immunotherapy (LIT).We performed a retrospective observational study of women with a history of two or more consecutive miscarriages who underwent LIT. All patients had undergone investigation of the etiology of the pregnancy losses according to a specific protocol. These etiologic factors were compared between those whose pregnancy outcome was successful and those who had a further miscarriage. The comparison between the groups was performed by Kruskal-Wallis, Fisher exact and Chi-square tests. Perinatal outcome data were collected for the successful pregnancies.One-hundred six patients were included. The mean number (±SD) of previous pregnancies, deliveries and miscarriages in all patients were 2.73 ± 0.8, 0.19 ± 0.4 and 2.54 ± 0.6, respectively. A successful pregnancy outcome after lymphocyte therapy occurred in 82 patients (group I), while 24 (22.6%) sustained a further miscarriage (group II). There was no statistical difference in the genetic, anatomic and hormonal causes of miscarriage between the groups (p 0.05). Antinuclear (ANA) and antithyroglobulin (TgAb) autoantibodies occurred more frequently in group II (p = 0.0010 and p = 0.0024, respectively). Of those with successful pregnancies, 11 women (13.4%) had a preterm delivery. The mean birth weight was 3036.4 ± 498.6 g.In patients with recurrent miscarriage treated with LIT, the presence of ANA and TgAb was a risk factor for further pregnancy loss. Perinatal outcomes in those whose pregnancies continued were favorable.
- Published
- 2014
23. Risk factors for death and changing patterns in leptospirosis acute renal failure
- Author
-
Dirce Maria Trevisan Zanetta, Marcelo Borges Cavalcante, Elizabeth De Francesco Daher, and Regina C. R. M. Abdulkader
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Oliguria ,Blood Pressure ,Sex Factors ,Risk Factors ,Virology ,Internal medicine ,medicine ,Humans ,Respiratory sounds ,Risk factor ,Child ,Intensive care medicine ,Aged ,Respiratory Sounds ,Retrospective Studies ,Aged, 80 and over ,Leptospira ,medicine.diagnostic_test ,business.industry ,Age Factors ,Acute kidney injury ,Arrhythmias, Cardiac ,Retrospective cohort study ,Odds ratio ,Acute Kidney Injury ,Middle Aged ,medicine.disease ,Dyspnea ,Infectious Diseases ,Female ,Parasitology ,medicine.symptom ,Weil Disease ,business ,Brazil ,Kidney disease - Abstract
The risk factors for death and changes in clinical patterns in leptospirosis (Weil's disease) have not been well studied. We retrospectively studied 110 patients with Weil's disease hospitalized in Brazil between 1985 and 1996. Univariate statistical analysis showed that nonsurvivors were older than survivors, and had higher frequency of oliguria, cardiac arrhythmia, dyspnea, and pulmonary rales. Logistic regression showed that the only independent factor associated with death was oliguria (odds ratio [OR] = 8.98). The presence of arthralgia (OR = 4.71), dehydration (OR = 6.26), dyspnea (OR = 17.7), and pulmonary rales (OR = 9.91) increased after 1994. These data suggest that in Weil's disease the clinical patterns have changed and the presence of oliguria is a risk factor for death.
- Published
- 1999
24. Etiological factors associated with alloimmunity in women with recurrent miscarriage
- Author
-
Ricardo Barini Cavalcante, Marcelo Borges Cavalcante, and Candice Torres de Melo Bezerra
- Subjects
medicine.medical_specialty ,Reproductive Medicine ,business.industry ,Obstetrics ,Immunology ,Recurrent miscarriage ,Alloimmunity ,Etiology ,Obstetrics and Gynecology ,Immunology and Allergy ,Medicine ,business ,medicine.disease - Published
- 2014
25. Interferência da idade sobre a qualidade seminal
- Author
-
Marjorie Luzia Custódio Mota Dias, Marcelo de Pontes Rocha, Oswaldo José Queiroz Dias, Danielle Oliveira de Araújo Souza, Iara Gonçalves Roberto, and Marcelo Borges Cavalcante
- Subjects
Gynecology ,Gerontology ,Semen quality ,medicine.medical_specialty ,business.industry ,medicine ,Grupos etários ,Contagem de espermatozóides ,Motilidade espermática ,Obstetrics and Gynecology ,business ,Morfologia ,Sêmen - Abstract
OBJETIVO: avaliar a influencia da idade sobre a qualidade seminal de homens com quadro de infertilidade conjugal submetidos a analises espermaticas em um servico de reproducao humana. METODOS: estudo retrospectivo, no qual foram avaliados os espermogramas de todos os homens em processo de investigacao para infertilidade conjugal no periodo de Setembro de 2002 a Dezembro de 2004, em um servico de reproducao assistida do nordeste do Brasil. Foram incluidos 531 individuos submetidos a 531 avaliacoes espermaticas. Foram analisados os seguintes parâmetros: volume, concentracao, motilidade e morfologia espermatica. O total de investigados foi dividido em grupos, de acordo com resultados obtidos de cada variavel estudada. Os grupos referentes ao volume seminal foram: hipoespermia, normoespermia e hiperespermia. Os grupos referentes a concentracao espermatica foram: azoospermia, oligoospermia, normospermia e poliespermia. Os grupos referentes a motilidade foram: motilidade normal e astenospermia. Os grupos referentes a morfologia foram: morfologia normal e teratospermia. As medias das idades dos pacientes entre os grupos com parâmetros normais foram comparadas com as de grupos alterados, sendo utilizado o teste t. Para analise estatistica, foi utilizado o programa XLSTAT (p
- Published
- 2008
26. The number of previous miscarriage doesńt affects the autoantibodies profile and gestational outcomes in couples treated for recurrent miscarriages with paternal lymphocyte immunization
- Author
-
Marcelo Borges Cavalcante, Manoel Sarno, S. Batista, Candice Torres de Melo Bezerra Cavalcante, R. Galvao, Ricardo Barini, and P. Matheus
- Subjects
Gynecology ,medicine.medical_specialty ,Obstetrics ,business.industry ,Lymphocyte ,Immunology ,Autoantibody ,Obstetrics and Gynecology ,medicine.disease ,Miscarriage ,medicine.anatomical_structure ,Reproductive Medicine ,Immunization ,medicine ,Immunology and Allergy ,Gestation ,business - Published
- 2012
27. Pregnancy outcomes of couples treated for recurrent miscarriages with paternal lymphocyte immunization
- Author
-
Manoel Sarno, S. Batista, Candice Torres de Melo Bezerra Cavalcante, P. Matheus, Ricardo Barini, Marcelo Borges Cavalcante, and R. Galvao
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,Obstetrics ,Lymphocyte ,Immunology ,Obstetrics and Gynecology ,medicine.anatomical_structure ,Reproductive Medicine ,Immunization ,Immunology and Allergy ,Medicine ,business ,Pregnancy outcomes - Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.